Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 2/20 | 0.45 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10163027 | 0.82 | SLC18A3 (0.55) | JAK3SLC18A3HTR3A | |
| SCHEMBL10161173 | 0.79 | OPRM1 (0.46) | JAK3HTR3AOPRM1OPRD1OPRK1 | |
| SCHEMBL10162759 | 0.79 | HTR3A (0.49) | JAK3HTR3AUSP2CYP2D6 | |
| SCHEMBL10162739 | 0.78 | HTR3A (0.58) | JAK3SLC18A3HTR3A | |
| SCHEMBL10161191 | 0.76 | HTR3A (0.56) | JAK3SLC18A3HTR3A | |
| SCHEMBL27345562 | 0.76 | OPRL1 (0.56) | OPRM1OPRD1OPRK1OPRL1USP2 | |
| SCHEMBL10162841 | 0.76 | OPRL1 (0.43) | SLC18A3OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL10161177 | 0.76 | HTR3A (0.51) | JAK3SLC18A3HTR3A | |
| SCHEMBL10130919 | 0.74 | SLC6A2 (0.48) | OPRM1OPRD1OPRK1OPRL1CYP2D6 | |
| SCHEMBL10163585 | 0.74 | HTR3A (0.53) | JAK3HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | PANACEA BIOTEC LTD. (IN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165320-A1 | NOVEL AZABICYCLOHEXANES | CYP3A43, UGT1A1, CYP3A4 | JAK3 4653/4885SLC18A3 1584/4885HTR3A 852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.